- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Beyond Brexit What Awaits the UK Pharma
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Beyond Brexit What Awaits the UK Pharma will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Beyond Brexit What Awaits the UK Pharma VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Beyond Brexit What Awaits the UK Pharma VRIO Analysis shows that the financial resources of Beyond Brexit What Awaits the UK Pharma are highly valuable as these help in investing into external opportunities that arise. These also help Beyond Brexit What Awaits the UK Pharma in combating external threats.
- According to the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Beyond Brexit What Awaits the UK Pharma VRIO Analysis shows that Beyond Brexit What Awaits the UK Pharma's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Beyond Brexit What Awaits the UK Pharma's products.
- According to the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Beyond Brexit What Awaits the UK Pharma. These patents also provide Beyond Brexit What Awaits the UK Pharma with licensing revenue when it licenses these patents out to other manufacturers.
- The Beyond Brexit What Awaits the UK Pharma VRIO Analysis shows that Beyond Brexit What Awaits the UK Pharma’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Beyond Brexit What Awaits the UK Pharma. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Beyond Brexit What Awaits the UK Pharma VRIO Analysis shows that the research and development at Beyond Brexit What Awaits the UK Pharma is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Beyond Brexit What Awaits the UK Pharma. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Beyond Brexit What Awaits the UK Pharma are found to be rare according to the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Beyond Brexit What Awaits the UK Pharma VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Beyond Brexit What Awaits the UK Pharma and inhibit competitive advantage. This means that the local food products result in competitive parity for Beyond Brexit What Awaits the UK Pharma. As this resource is valuable, Beyond Brexit What Awaits the UK Pharma can still make use of this resource.
- The employees of Beyond Brexit What Awaits the UK Pharma are a rare resource as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Beyond Brexit What Awaits the UK Pharma are a rare resource as identified by the Beyond Brexit What Awaits the UK Pharma VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Beyond Brexit What Awaits the UK Pharma to use them without interference from the competition.
- The distribution network of Beyond Brexit What Awaits the UK Pharma is a rare resource as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Beyond Brexit What Awaits the UK Pharma. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Beyond Brexit What Awaits the UK Pharma are costly to imitate as identified by the Beyond Brexit What Awaits the UK Pharma VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Beyond Brexit What Awaits the UK Pharma provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Beyond Brexit What Awaits the UK Pharma are also not costly to imitate as identified by the Beyond Brexit What Awaits the UK Pharma VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Beyond Brexit What Awaits the UK Pharma by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Beyond Brexit What Awaits the UK Pharma a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Beyond Brexit What Awaits the UK Pharma are very difficult to imitate as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Beyond Brexit What Awaits the UK Pharma is also very costly to imitate by competition as identified by the Beyond Brexit What Awaits the UK Pharma VRIO Analysis. This has been developed over the years gradually by Beyond Brexit What Awaits the UK Pharma. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Beyond Brexit What Awaits the UK Pharma are organised to capture value as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Beyond Brexit What Awaits the UK Pharma.
- The Patents of Beyond Brexit What Awaits the UK Pharma are not well organised as identified by the Beyond Brexit What Awaits the UK Pharma VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Beyond Brexit What Awaits the UK Pharma starts selling patented products before the patents expire.
- The distribution network of Beyond Brexit What Awaits the UK Pharma is organised as identified by the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma. Beyond Brexit What Awaits the UK Pharma uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Beyond Brexit What Awaits the UK Pharma.
From the VRIO Analysis of Beyond Brexit What Awaits the UK Pharma, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Beyond Brexit What Awaits the UK Pharma is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Asyraff Adriel
5.0
Anyone could scarcely find a service that offers lots of features. It was really difficult for me to form the assignment. A very good service!
Summer Hudson
5.0
All types of paper are provided by this company and I'm happy with this company. Thanks a lot!
Giuseppe Mauro
5.0
I obtained a perfectly written term paper within the deadline. The quality was good and all details were checked. Thanks a lot!
Zhang Yong
5.0
Excellent work! This essay writing service exactly knows how to do its work. Thank you very much!
Next Articles
- SOBHA Limited: Building Brand Brick By Brick Vrio Analysis
- Kingdee In 2011: Stranding Or Dormancy? Vrio Analysis
- Beyondsoft Co, Ltd (B) Vrio Analysis
- Beyondsoft IPO (A) And (B) Vrio Analysis
- Beyondsoft IPO (A) Vrio Analysis
- Beyondsoft IPO (B) Vrio Analysis
- Beyondsoft Co, Ltd (A) Vrio Analysis
- Microsoft Participações Vrio Analysis
- Customer Acquisition At Castlight Health, Inc Vrio Analysis
- Seeking Balance Between Social Purpose And Entrepreneurship: Homeland Development Initiative Foundation Vrio Analysis
Previous Articles
- Sweden's Cashless Economy: A Model To Emulate? Vrio Analysis
- Türk Telekom Deploys TEOCO: A Move To Provide Differentiated Customer Experience Vrio Analysis
- Idea Cellular Vodafone Merger: A Win Win Deal? Vrio Analysis
- Gender Lens Investing: Exemplar Of Social Change Vrio Analysis
- Internet Use In Vernacular Languages: The Ripple Effect Vrio Analysis
- Cineworld's Takeover Of Regal: A Strategic Move? Vrio Analysis
- Old Monk: The Brand Forever Vrio Analysis
- Dubai's Rising Inflation: What The Index Portends? Vrio Analysis
- Apple Slowing Down Older IPhones: A Wise Business Strategy? Vrio Analysis
- The Tide Pod Challenge: A Brand Crisis For P&G? Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!